BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35912169)

  • 1. The Prognostic Value of Tumor Size, Volume and Tumor Volume Reduction Rate During Concurrent Chemoradiotherapy in Patients With Cervical Cancer.
    Sun C; Wang S; Ye W; Wang R; Tan M; Zhang H; Zhou J; Li M; Wei L; Xu P; Zhu G; Lang J; Lu S
    Front Oncol; 2022; 12():934110. PubMed ID: 35912169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients: a multi-institutional retrospective analysis of KROG 16-01.
    Lee JH; Lee SW; Kim JR; Kim YS; Yoon MS; Jeong S; Kim JH; Lee JY; Eom KY; Jeong BK; Lee SH
    Gynecol Oncol; 2017 Dec; 147(3):577-584. PubMed ID: 29110878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer.
    Chen W; Xiu S; Xie X; Guo H; Xu Y; Bai P; Xia X
    Radiat Oncol; 2022 Jan; 17(1):6. PubMed ID: 35012582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging after external beam radiotherapy and concurrent chemotherapy for locally advanced cervical cancer helps to identify patients at risk of recurrence.
    Angeles MA; Baissas P; Leblanc E; Lusque A; Ferron G; Ducassou A; Martínez-Gómez C; Querleu D; Martinez A
    Int J Gynecol Cancer; 2019 Mar; 29(3):480-486. PubMed ID: 30712019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI-based volumetric tumor parameters before and during chemoradiation predict tumor recurrence and patient survival in locally advanced cervical cancer: a subgroup analysis of a phase II prospective trial.
    Kang HB; Kim SH; Lee JH; Lee HC; Kang NK; Lee JH
    Int J Clin Oncol; 2024 May; 29(5):620-628. PubMed ID: 38530569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors in definitive radiotherapy of uterine cervical cancer.
    Yalman D; Aras AB; Ozkök S; Duransoy A; Celik OK; Ozsaran Z; Haydaroğlu A
    Eur J Gynaecol Oncol; 2003; 24(3-4):309-14. PubMed ID: 12807246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
    Binbin T; Lingying W; Manni H; Jusheng A; Ning L
    Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Volume Reduction Rate during Adaptive Radiation Therapy as a Prognosticator for Nasopharyngeal Cancer.
    Lee H; Ahn YC; Oh D; Nam H; Noh JM; Park SY
    Cancer Res Treat; 2016 Apr; 48(2):537-45. PubMed ID: 26194371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
    Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
    J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
    Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
    [No Abstract]   [Full Text] [Related]  

  • 12. Concurrent chemoradiotherapy with nedaplatin in patients with stage IIA to IVA cervical carcinoma.
    Fujioka T; Yasuoka T; Koizumi M; Tanaka H; Hashimoto H; Nabeta M; Koizumi K; Matsubara Y; Hamada K; Matsubara K; Katayama T; Nawa A
    Mol Clin Oncol; 2013 Jan; 1(1):165-170. PubMed ID: 24649141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
    Ma R; Zhang H; Zou L; Qu Y
    Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI-based radiomics: promise for locally advanced cervical cancer treated with a tailored integrated therapeutic approach.
    Laliscia C; Gadducci A; Mattioni R; Orlandi F; Giusti S; Barcellini A; Gabelloni M; Morganti R; Neri E; Paiar F
    Tumori; 2022 Aug; 108(4):376-385. PubMed ID: 34235995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose-rate brachytherapy boost for locally advanced cervical cancer: Oncological outcome and toxicity analysis of 4 fractionation schemes.
    le Guyader M; Lam Cham Kee D; Thamphya B; Schiappa R; Gautier M; Chand-Fouche ME; Hannoun-Levi JM
    Clin Transl Radiat Oncol; 2022 Jan; 32():15-23. PubMed ID: 34816022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI.
    Nam H; Park W; Huh SJ; Bae DS; Kim BG; Lee JH; Lee JW; Lim DH; Han Y; Park HC; Ahn YC
    Gynecol Oncol; 2007 Nov; 107(2):320-5. PubMed ID: 17675222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes following conventional external beam radiotherapy boost in Japanese patients with cervical cancer who are ineligible for intracavitary brachytherapy.
    Ito K; Shimizuguchi T; Karasawa K
    Jpn J Clin Oncol; 2019 Mar; 49(3):270-275. PubMed ID: 30576504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic effect of tumor volume, reduction ratio, and cumulative doses on external beam radiotherapy with central-shielding method and image-guided adaptive brachytherapy for cervical cancer.
    Ohtaka T; Ando K; Oike T; Noda SE; Kaminuma T; Murata K; Ohno T
    Front Oncol; 2024; 14():1366777. PubMed ID: 38774419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FIGO Classification 2018: Validation Study in Patients With Locally Advanced Cervix Cancer Treated With Chemoradiation.
    Raut A; Chopra S; Mittal P; Patil G; Mahantshetty U; Gurram L; Swamidas J; Ghosh J; Gulia S; Popat P; Deodhar K; Maheshwari A; Gupta S
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1248-1256. PubMed ID: 32681859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of concurrent chemoradiotherapy followed by radical surgery and high-dose-rate intracavitary brachytherapy: a retrospective study of 240 patients with FIGO stage IIB cervical carcinoma.
    Wang N; Li WW; Li JP; Liu JY; Zhou YC; Zhang Y; Hu J; Huang YH; Chen Y; Wei LC; Shi M
    Onco Targets Ther; 2014; 7():91-100. PubMed ID: 24421644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.